Fig. 1From: Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational studyThe probability of filter survival by the nafamostat mesylate dosage plotted in the Kaplan-Meier curve. Adjusted for bleeding risk and haemofiltration. Group H received nafamostat mesylate at the dose of ≥ 20 mg/hr. Group L received nafamostat mesylate at the dose of < 20 mg/hrBack to article page